Marc Lambelet

470 total citations
22 papers, 311 citations indexed

About

Marc Lambelet is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Marc Lambelet has authored 22 papers receiving a total of 311 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Cardiology and Cardiovascular Medicine, 8 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marc Lambelet's work include Atrial Fibrillation Management and Outcomes (10 papers), Cardiac Arrhythmias and Treatments (7 papers) and Hormonal Regulation and Hypertension (6 papers). Marc Lambelet is often cited by papers focused on Atrial Fibrillation Management and Outcomes (10 papers), Cardiac Arrhythmias and Treatments (7 papers) and Hormonal Regulation and Hypertension (6 papers). Marc Lambelet collaborates with scholars based in Germany, United States and France. Marc Lambelet's co-authors include Sylvia Haas, Susanne Hess, Pierre Amarenco, Paulus Kirchhof, Luís M. Ruilope, Gerasimos Filippatos, Peter Rossing, Bertram Pitt, Stefan D. Anker and A. John Camm and has published in prestigious journals such as Journal of the American College of Cardiology, Journal of the American Society of Nephrology and European Heart Journal.

In The Last Decade

Marc Lambelet

21 papers receiving 305 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marc Lambelet Germany	11	212	120	68	56	40	22	311
Kensuke Matsushita France	10	145 0.7×	71 0.6×	23 0.3×	52 0.9×	44 1.1×	32	349
Helen Tesfaye United States	9	37 0.2×	97 0.8×	33 0.5×	32 0.6×	36 0.9×	24	199
Priyanka Kakar United States	9	145 0.7×	101 0.8×	51 0.8×	53 0.9×	22 0.6×	13	328
Tabassome Simon France	8	243 1.1×	62 0.5×	23 0.3×	55 1.0×	11 0.3×	16	310
Amanda Fernandes United States	9	269 1.3×	179 1.5×	53 0.8×	8 0.1×	84 2.1×	26	403
Hiroyuki Tanaka Japan	8	117 0.6×	133 1.1×	63 0.9×	27 0.5×	54 1.4×	17	362
C. Kreilick United States	8	233 1.1×	73 0.6×	42 0.6×	65 1.2×	25 0.6×	15	343
Sheliang Xue China	7	107 0.5×	96 0.8×	40 0.6×	10 0.2×	28 0.7×	14	277
Alain Gay Germany	11	146 0.7×	183 1.5×	61 0.9×	19 0.3×	54 1.4×	22	369
Athanasios Samaras Greece	12	397 1.9×	43 0.4×	16 0.2×	24 0.4×	23 0.6×	54	474

Countries citing papers authored by Marc Lambelet

Since Specialization

Citations

This map shows the geographic impact of Marc Lambelet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Lambelet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Lambelet more than expected).

Fields of papers citing papers by Marc Lambelet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Lambelet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Lambelet. The network helps show where Marc Lambelet may publish in the future.

Co-authorship network of co-authors of Marc Lambelet

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Lambelet. A scholar is included among the top collaborators of Marc Lambelet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Lambelet. Marc Lambelet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Singh, Ajay, Stefan D. Anker, Peter Rossing, et al.. (2025). A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD. Kidney International Reports. 11(3). 103704–103704.

Ferreira, João Pedro, Stefan D. Anker, Biff F. Palmer, et al.. (2025). Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programme. European Heart Journal. 2 indexed citations

Pitt, Bertram, Rajiv Agarwal, Stefan D. Anker, et al.. (2024). Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone—a FIDELITY analysis. European Heart Journal - Cardiovascular Pharmacotherapy. 11(1). 10–19. 1 indexed citations

Singh, Ajay, Stefan D. Anker, Bertram Pitt, et al.. (2024). Finerenone in Patients with Type 2 Diabetes and CKD by SGLT2 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonists Receptor Agonist Use: A FIDELITY Analysis. Journal of the American Society of Nephrology. 35(10S). 1 indexed citations

Kirchhof, Paulus, Sylvia Haas, Pierre Amarenco, et al.. (2024). Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS. EP Europace. 26(7). 4 indexed citations

Benza, Raymond L., Harrison W. Farber, Adaani Frost, et al.. (2022). Application of the REVEAL risk score calculator 2.0 in the CHEST study. Respiratory Medicine. 195. 106783–106783. 2 indexed citations

Filippatos, Gerasimos, Stefan D. Anker, Bertram Pitt, et al.. (2022). Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes. JACC Heart Failure. 10(11). 860–870. 43 indexed citations

Pitt, Bertram, Rajiv Agarwal, Stefan D. Anker, et al.. (2022). Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease. JAMA Network Open. 5(10). e2236123–e2236123. 11 indexed citations

Agarwal, Rajiv, Luís M. Ruilope, Gema Ruiz‐Hurtado, et al.. (2022). Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. Journal of Hypertension. 41(2). 295–302. 49 indexed citations

10.

Benza, Raymond L., Athénaïs Boucly, Harrison W. Farber, et al.. (2021). Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study. The Journal of Heart and Lung Transplantation. 41(3). 411–420. 7 indexed citations

11.

Benza, Raymond L., Harrison W. Farber, Adaani Frost, et al.. (2021). Application of the REVEAL risk score calculator 2.0 in the PATENT study. International Journal of Cardiology. 332. 189–192. 8 indexed citations

12.

Camm, A. John, Pierre Amarenco, Sylvia Haas, et al.. (2020). Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study. Clinical Cardiology. 43(12). 1405–1413. 2 indexed citations

13.

Kirchhof, Paulus, Sylvia Haas, Pierre Amarenco, et al.. (2020). Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. Journal of the American Heart Association. 9(5). e009530–e009530. 23 indexed citations

14.

Heinig, Roland, et al.. (2019). Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment. European Journal of Drug Metabolism and Pharmacokinetics. 44(5). 619–628. 21 indexed citations

15.

Laņas, Fernando, et al.. (2018). XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America. The Egyptian Heart Journal. 70(4). 307–313. 17 indexed citations

16.

Kirchhof, Paulus, Young‐Hoon Kim, Fernando Laņas, et al.. (2018). Global Prospective Safety Analysis of Rivaroxaban. Journal of the American College of Cardiology. 72(2). 141–153. 41 indexed citations

17.

Amarenco, Pierre, Sylvia Haas, Susanne Hess, et al.. (2018). Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. European Heart Journal - Cardiovascular Pharmacotherapy. 5(2). 70–79. 24 indexed citations

18.

Camm, A. John, Pierre Amarenco, Sylvia Haas, et al.. (2017). REAL-WORLD VERSUS RANDOMIZED TRIAL OUTCOMES IN SIMILAR POPULATIONS OF RIVAROXABAN-TREATED PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN ROCKET AF AND XANTUS. Journal of the American College of Cardiology. 69(11). 438–438. 1 indexed citations

19.

Camm, A. John, Alexander G.G. Turpie, Susanne Hess, et al.. (2017). Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. EP Europace. 20(6). e87–e95. 12 indexed citations

20.

Kirchhof, Paulus, Yeul Hong Kim, Fernando Laņas, et al.. (2017). P3592Safety analysis of rivaroxaban: a pooled analysis of the global XANTUS programme (real-world, prospective, observational studies for stroke prevention in patients with atrial fibrillation). European Heart Journal. 38(suppl_1). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact